BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 31604676)

  • 1. Long-Term Structural Outcomes of Late-Stage RPE65 Gene Therapy.
    Gardiner KL; Cideciyan AV; Swider M; Dufour VL; Sumaroka A; Komáromy AM; Hauswirth WW; Iwabe S; Jacobson SG; Beltran WA; Aguirre GD
    Mol Ther; 2020 Jan; 28(1):266-278. PubMed ID: 31604676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement.
    Cideciyan AV; Jacobson SG; Beltran WA; Sumaroka A; Swider M; Iwabe S; Roman AJ; Olivares MB; Schwartz SB; Komáromy AM; Hauswirth WW; Aguirre GD
    Proc Natl Acad Sci U S A; 2013 Feb; 110(6):E517-25. PubMed ID: 23341635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness.
    Acland GM; Aguirre GD; Bennett J; Aleman TS; Cideciyan AV; Bennicelli J; Dejneka NS; Pearce-Kelling SE; Maguire AM; Palczewski K; Hauswirth WW; Jacobson SG
    Mol Ther; 2005 Dec; 12(6):1072-82. PubMed ID: 16226919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Status of RPE65 Gene Therapy Trials: Safety and Efficacy.
    Pierce EA; Bennett J
    Cold Spring Harb Perspect Med; 2015 Jan; 5(9):a017285. PubMed ID: 25635059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of gene therapy on Leber's congenital amaurosis.
    Bainbridge JW; Mehat MS; Sundaram V; Robbie SJ; Barker SE; Ripamonti C; Georgiadis A; Mowat FM; Beattie SG; Gardner PJ; Feathers KL; Luong VA; Yzer S; Balaggan K; Viswanathan A; de Ravel TJ; Casteels I; Holder GE; Tyler N; Fitzke FW; Weleber RG; Nardini M; Moore AT; Thompson DA; Petersen-Jones SM; Michaelides M; van den Born LI; Stockman A; Smith AJ; Rubin G; Ali RR
    N Engl J Med; 2015 May; 372(20):1887-97. PubMed ID: 25938638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Amelioration of Cone Survival and Vision in a Mouse Model for Leber Congenital Amaurosis.
    Li S; Samardzija M; Yang Z; Grimm C; Jin M
    J Neurosci; 2016 May; 36(21):5808-19. PubMed ID: 27225770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy.
    Pennesi ME; Weleber RG; Yang P; Whitebirch C; Thean B; Flotte TR; Humphries M; Chegarnov E; Beasley KN; Stout JT; Chulay JD
    Hum Gene Ther; 2018 Dec; 29(12):1428-1437. PubMed ID: 29869534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful gene therapy in older Rpe65-deficient dogs following subretinal injection of an adeno-associated vector expressing RPE65.
    Annear MJ; Mowat FM; Bartoe JT; Querubin J; Azam SA; Basche M; Curran PG; Smith AJ; Bainbridge JW; Ali RR; Petersen-Jones SM
    Hum Gene Ther; 2013 Oct; 24(10):883-93. PubMed ID: 24028205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA).
    Pang JJ; Chang B; Hawes NL; Hurd RE; Davisson MT; Li J; Noorwez SM; Malhotra R; McDowell JH; Kaushal S; Hauswirth WW; Nusinowitz S; Thompson DA; Heckenlively JR
    Mol Vis; 2005 Feb; 11():152-62. PubMed ID: 15765048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety in nonhuman primates of ocular AAV2-RPE65, a candidate treatment for blindness in Leber congenital amaurosis.
    Jacobson SG; Boye SL; Aleman TS; Conlon TJ; Zeiss CJ; Roman AJ; Cideciyan AV; Schwartz SB; Komaromy AM; Doobrajh M; Cheung AY; Sumaroka A; Pearce-Kelling SE; Aguirre GD; Kaushal S; Maguire AM; Flotte TR; Hauswirth WW
    Hum Gene Ther; 2006 Aug; 17(8):845-58. PubMed ID: 16942444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Photoreceptor layer topography in children with leber congenital amaurosis caused by RPE65 mutations.
    Jacobson SG; Cideciyan AV; Aleman TS; Sumaroka A; Windsor EA; Schwartz SB; Heon E; Stone EM
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4573-7. PubMed ID: 18539930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinal disease in Rpe65-deficient mice: comparison to human leber congenital amaurosis due to RPE65 mutations.
    Caruso RC; Aleman TS; Cideciyan AV; Roman AJ; Sumaroka A; Mullins CL; Boye SL; Hauswirth WW; Jacobson SG
    Invest Ophthalmol Vis Sci; 2010 Oct; 51(10):5304-13. PubMed ID: 20484585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying photoreceptors in blind eyes caused by RPE65 mutations: Prerequisite for human gene therapy success.
    Jacobson SG; Aleman TS; Cideciyan AV; Sumaroka A; Schwartz SB; Windsor EA; Traboulsi EI; Heon E; Pittler SJ; Milam AH; Maguire AM; Palczewski K; Stone EM; Bennett J
    Proc Natl Acad Sci U S A; 2005 Apr; 102(17):6177-82. PubMed ID: 15837919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood-Onset Retinal Dystrophy.
    Weleber RG; Pennesi ME; Wilson DJ; Kaushal S; Erker LR; Jensen L; McBride MT; Flotte TR; Humphries M; Calcedo R; Hauswirth WW; Chulay JD; Stout JT
    Ophthalmology; 2016 Jul; 123(7):1606-20. PubMed ID: 27102010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years.
    Jacobson SG; Cideciyan AV; Ratnakaram R; Heon E; Schwartz SB; Roman AJ; Peden MC; Aleman TS; Boye SL; Sumaroka A; Conlon TJ; Calcedo R; Pang JJ; Erger KE; Olivares MB; Mullins CL; Swider M; Kaushal S; Feuer WJ; Iannaccone A; Fishman GA; Stone EM; Byrne BJ; Hauswirth WW
    Arch Ophthalmol; 2012 Jan; 130(1):9-24. PubMed ID: 21911650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered expression of retinal molecular markers in the canine RPE65 model of Leber congenital amaurosis.
    Hernández M; Pearce-Kelling SE; Rodriguez FD; Aguirre GD; Vecino E
    Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6793-802. PubMed ID: 20671290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The findings of optical coherence tomography of retinal degeneration in relation to the morphological and electroretinographic features in RPE65-/- mice.
    Tanabu R; Sato K; Monai N; Yamauchi K; Gonome T; Xie Y; Takahashi S; Ishiguro SI; Nakazawa M
    PLoS One; 2019; 14(1):e0210439. PubMed ID: 30695025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation.
    Aguirre GK; Komáromy AM; Cideciyan AV; Brainard DH; Aleman TS; Roman AJ; Avants BB; Gee JC; Korczykowski M; Hauswirth WW; Acland GM; Aguirre GD; Jacobson SG
    PLoS Med; 2007 Jun; 4(6):e230. PubMed ID: 17594175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy.
    Cideciyan AV
    Prog Retin Eye Res; 2010 Sep; 29(5):398-427. PubMed ID: 20399883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lentiviral gene transfer of RPE65 rescues survival and function of cones in a mouse model of Leber congenital amaurosis.
    Bemelmans AP; Kostic C; Crippa SV; Hauswirth WW; Lem J; Munier FL; Seeliger MW; Wenzel A; Arsenijevic Y
    PLoS Med; 2006 Oct; 3(10):e347. PubMed ID: 17032058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.